Advancing Treatment for C3G; Targeting the Complement System for Personalized Kidney Care - Episode 13
Panelists discuss how the APPEAR-C3G trial demonstrated that iptacopan significantly reduced proteinuria by 35% at 6 months, was well tolerated with no new safety signals over 12 months, slowed glomerular filtration rate (GFR) decline, and showed a statistically significant reduction in glomerular C3 deposit scores, though detailed biopsy clearance rates were not reported.
Video content above is prompted by the following:
APPEAR-C3G Trial Summary: Iptacopan in C3 Glomerulopathy
Study Design
Primary Outcome
Biopsy and Histologic Findings
Notable Observations
Conclusion
Iptacopan demonstrated clear efficacy in reducing proteinuria, improving complement activity markers, and possibly slowing renal function decline in C3G. The trial supports its safety and potential role in managing patients with complement-driven glomerulopathies.